Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.56 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13138964 | 0.86 | HCRTR1 (0.48) | HCRTR1HCRTR2NLRP3POLB | |
| SCHEMBL2011001 | 0.86 | HCRTR1 (0.59) | HCRTR1HCRTR2NPC1RAB9APOLB | |
| SCHEMBL2013002 | 0.86 | HCRTR1 (0.57) | HCRTR1HCRTR2NPC1RAB9A | |
| SCHEMBL2014627 | 0.85 | HCRTR1 (0.59) | HCRTR1HCRTR2NPC1RAB9ANLRP3 | |
| SCHEMBL6918074 | 0.85 | HCRTR1 (0.59) | HCRTR1HCRTR2NPC1RAB9ANLRP3 | |
| SCHEMBL2013021 | 0.85 | HCRTR1 (0.57) | HCRTR1HCRTR2NPC1RAB9APOLB | |
| SCHEMBL2017397 | 0.83 | HCRTR1 (0.57) | HCRTR1HCRTR2NPC1RAB9ANLRP3 | |
| SCHEMBL2010539 | 0.81 | HCRTR1 (0.63) | HCRTR1HCRTR2NPC1RAB9APOLB | |
| SCHEMBL2013001 | 0.80 | HCRTR1 (0.56) | HCRTR1HCRTR2NPC1RAB9A | |
| SCHEMBL13139060 | 0.80 | HCRTR1 (0.77) | HCRTR1HCRTR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011073316-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | claimed |
| WO-2011073316-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | disclosed |